29 results about "Pathogenic Escherichia coli" patented technology

The invention discloses a high-strength nano-composite antibacterial fabric which comprises a base fabric and a modified and sol-gel nano layer, the modified and sol-gel nano layer and the base fabric are compounded and smeared to form the nano-composite antibacterial fabric, and the modified and sol-gel nano layer is coated with the modified and sol-gel nano layer to form the high-strength nano-composite antibacterial fabric. The modified sol-gel nano layer comprises titanium dioxide sol, nano zinc oxide and a silver antibacterial agent, the base layer fabric is prepared from the following raw materials in percentage by weight: 10% of chitin fiber, 50% of Coolplus fiber, 40% of cotton fiber and 16.7 tex of yarn linear density, and the base layer fabric is prepared from the following raw materials in percentage by weight: 10% of chitosan fiber, 50% of Coolplus fiber, 40% of cotton fiber and 16.7 tex of yarn linear density. Compared with the prior art, the fabric has the advantages that a layer of uniform and firm porous nano antibacterial film is formed on the surface of the fabric, so that staphylococcus aureus and pathogenic escherichia coli can be effectively killed; the double-layer fabric formed by combining the chitin fibers, the Coolplus fibers and the cotton fibers has good antibacterial, bacteriostatic, rapid moisture absorption and moisture conduction functions.

A method for preparing a bacteriophage targeting extra-intestinal pathogenic Escherichia coli (ExPEC) comprising mixing pig (porcine) extraintestinal E. coli host cells at logarithmic phase with phage

The invention discloses a traditional Chinese medicine composition for preventing and treating avian pathogenic escherichia coli as well as a preparation method and application thereof, and relates to the technical field of veterinary drugs. According to the invention, screening is carried out through subtraction genomics and reverse network pharmacology, and based on the compatibility theory of monarch, minister, assistant and guide and the traditional Chinese veterinary medicine and pharmacy differentiation theory, a traditional Chinese medicine composition, namely the radix angelicae and fructus forsythiae intestine health formula, for preventing and treating avian pathogenic escherichia coli is formed. According to the traditional Chinese medicine composition, fructus forsythiae and radix angelicae are used as monarch drugs, radix isatidis and clinopodium polycephalum are used as ministerial drugs, fructus aurantii immaturus, mint and plantain herb are used as adjuvant drugs, and liquorice is used as a conductant drug, so that the traditional Chinese medicine composition can inhibit reproduction of avian pathogenic escherichia coli, destroy formation of biological membranes of the avian pathogenic escherichia coli and relieve pathological injuries of diseased poultry caused by APEC; the traditional Chinese medicine composition has a good treatment effect on avian pathogenic escherichia coli.

The invention relates to the technical field of microorganisms, in particular to an escherichia coli bacteriophage for improving the antibacterial effect of cecropin and application of the escherichia coli bacteriophage. The bacteriophage is named as RDP-EC-22139, the genome of the bacteriophage does not contain virulence genes and lyogenicity related genes, and the bacteriophage has good biological safety. The bacteriophage has relatively strong lysis activity on drug-resistant pathogenic escherichia coli, can still keep stable lysis titer in a relatively wide temperature and pH condition range, and has good genetic stability. When the bacteriophage is combined with cecropin for use, the minimum inhibitory concentration of the cecropin on drug-resistant pathogenic escherichia coli is remarkably reduced, the minimum inhibitory concentration can be reduced to 1 / 2-1 / 8 of the minimum inhibitory concentration when the cecropin is independently used, the inhibition time on pathogenic bacteria is remarkably prolonged, and a stable and unexpected synergistic antibacterial effect is shown. The invention provides a safe and effective biological technical scheme for prevention and control of drug-resistant Escherichia coli infection, and has a good application prospect.

The invention discloses a bacteriophage capable of splitting pathogenic escherichia coli and application of the bacteriophage. The phage is named as Escherichia coli phage vBEcoMYS1, and is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the phage is GDMCC No: 67465-B1vBEcoMYS1. Experiments prove that the bacteriophage has relatively strong splitting capacity, relatively strong thermal stability and relatively strong pH stability, and can keep high titer under the conditions that the temperature is 4-40 DEG C and the pH is 5-9. The bacteriophage can be used for splitting multiple escherichia coli, including enterotoxigenic escherichia coli (ETEC) and shiga toxin-producing escherichia coli (STEC), has a relatively wide splitting spectrum, and can be used as an antibiotic substitute. In addition, the genome of the bacteriophage does not contain virulence genes and antibiotic resistance genes, so that the bacteriophage has good biological safety.

The invention relates to the technical field of molecular biomedicine, in particular to a method for identifying enteropathogenic Escherichia coli, which comprises the following steps: screening virulence genes, determining a Cutom Markers gene, detecting mNGS of a clinical specimen, comparing off-machine data and identifying the enteropathogenic Escherichia coli. The specificity of the identification method reaches 99.9%, and the sensitivity reaches 96.8% when the detection sequence of escherichia coli is greater than or equal to 10k reads. By utilizing the method, the accuracy and applicability of enteropathogenic escherichia coli identification can be remarkably improved, and the method can be widely applied to the field of clinical microbiological detection.

The application belongs to the technical field of bioengineering, and particularly relates to a bacteriophage PE-2 of Escherichia coli with high blood entry efficiency and fermentation efficiency and application. The bacteriophage involved in the application has a preservation number of CCTCC NO: M20252973, and can specifically lyse pathogenic Escherichia coli O2 serotype and has high blood entry efficiency. The bacteriophage can enter blood circulation through oral administration, and can be widely distributed to the spleen, liver, heart and other tissues through blood circulation. The bacteriophage can be prepared in pilot production to obtain a very high titer, and the titer reaches 1.6x10 12 PFU / mL. Compared with the production of antibiotics, the production cost of the bacteriophage is low, and the bacteriophage provides a source and a reference example for industrial production of high-titer bacteriophage.

The invention provides a kit for detecting multiple piglet diarrhea pathogens and a detection method, and belongs to the technical field of biological information detection. The kit comprises a reaction reagent, wherein the reaction reagent comprises a porcine epidemic diarrhea virus specific primer and a probe, a porcine delta coronavirus specific primer and a probe, a piglet pathogenic escherichia coli specific primer and a probe, a clostridium perfringens specific primer and a probe, a buffer solution, an enzyme mixed solution and a freeze-drying protective additive. The detection method adopts the kit for detecting various piglet diarrhea pathogens. According to the kit disclosed by the invention, simultaneous detection of four target genes including the porcine epidemic diarrhea virus, the porcine delta coronavirus, the piglet pathogenic escherichia coli and the clostridium perfringens can be realized only through one-time amplification, so that the detection time is greatly shortened while the detection cost is reduced; the kit has extremely high specificity, sensitivity and repeatability, and the primers and the probes do not interfere with each other; good normal-temperature storage stability is also realized.

The invention discloses a strain of leuconostoc mesenteroides V7, and the microbial preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34824. The leuconostoc mesenteroides V7 disclosed by the invention is applied to products for inhibiting source avian pathogenic escherichia coli. The leuconostoc mesenteroides V7 disclosed by the invention has an inhibition effect on avian pathogenic escherichia coli, so that the leuconostoc mesenteroides V7 can be used for replacing antibiotics in poultry production and breeding to treat avian pathogenic colibacillosis. The invention provides a novel antibiotic substitute, which can obviously improve the infection condition of avian pathogenic escherichia coli in poultry bodies and avoid the problems of antibiotic abuse and bacterial drug resistance as much as possible.

The application discloses a dog-derived Enterococcus faecalis ZJUIDS-D016 with anti-aging effect and application, the dog-derived Enterococcus faecalis ZJUIDS-D016 is classified and named as (Enterococcus faecalis) Enterococcus faecalis ), and the preservation number is CGMCC 27038.The strain of the application is isolated from the intestinal tract of a healthy dog, has acid resistance, bile salt resistance and broad-spectrum antibacterial activity, and is sensitive to chloramphenicol, erythromycin and penicillin.The strain of the application has strong host adaptability, can colonize in the intestinal tract of a dog and secrete organic acids and bacteriocins, significantly inhibits the proliferation of common pathogenic bacteria such as dog pathogenic escherichia coli, effectively improves the intestinal health of pets and delays aging, and is suitable for preparing pet probiotic products.

The application discloses a protein molecule and application thereof in identifying avian pathogenic Escherichia coli of multiple serotypes, relates to the biological field, and the amino acid sequence of the protein molecule is shown as SEQ ID No:1. The protein molecule can specifically recognize avian pathogenic Escherichia coli of O2, O18 and O78 antigen serotypes, can be used for identifying avian pathogenic Escherichia coli of O2, O18 and O78 antigen serotypes, has the advantages of simplicity, rapidness, accuracy and the like, and has high application value.

The invention discloses a bacterial infection and LPS induced broiler chicken liver injury model and a construction method and application thereof, and the construction method comprises the following steps: administering 10-day-old broiler chicken with Escherichia coli E.coli O78 with a preset concentration in an intragastric administration manner; after broiler chickens are subjected to intragastric administration of escherichia coli for 18 hours, an LPS solution is injected into the intraperitoneal cavity of the broiler chickens, after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained, when the broiler chickens are 11 days old, the broiler chickens subjected to intragastric administration of escherichia coli are subjected to intraperitoneal injection of the LPS solution, and after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained. The broiler chicken liver injury model is constructed by intragastric administration of avian pathogenic escherichia coli (E.coli O78) and intraperitoneal injection of LPS (2 mg / kg), the pathology of the model is highly consistent with that of clinical broiler chicken bacterial liver injury, the liver has clinical typical lesions macroscopically, liver cells are degenerative and necrotic microscopically, and a molecular pathway activation mode is consistent with that of clinical application; the model constructed by the invention realizes specific liver injury, only the liver has specific injury, multiple organ lesions such as heart, peritoneum and the like do not exist, and the model availability is high.

Method for detecting pathogenic strains of Escherichia coli expressing the f17g gene of the F17 fimbria gene. The invention relates to a detection method based on the amplification of the genomic DNA of the pathogenic strain using LAMP technology with specific primers at a temperature of 62°C. This reaction is carried out with the Cas12a enzyme, previously activated with a guide RNA specific to the F17g gene. This method allows for the rapid detection of pathogenic strains with rudimentary equipment and can be associated with a rapid diagnostic device in the field.

The application discloses application of deacetylase inhibitor LMK235 in preparation of a medicine for treating chronic urinary tract infection and a medicine preparation thereof, and belongs to the field of biological medicines. The chronic urinary tract infection is induced by uropathogenic Escherichia coli. Experiments show that LMK235 can effectively reduce the amount of bacteria in urine and the amount of bacteria in the bladder by significantly reducing the colonization of uropathogenic Escherichia coli in the bladder in mice; and the chronic inflammation of the bladder caused by uropathogenic Escherichia coli infection can be improved by significantly reducing the level of inflammatory cytokine IL-1b in the bladder. The application widens the application field of the deacetylase inhibitor LMK235, provides an experimental basis for clinical application of LMK235 in preparation of a medicine for treating urinary system infection, and has a good application prospect, great potential value and social significance.

The application discloses a Salmonella phage nct1, and the Salmonella phage nct1 (Salmonella phage nct1) has a preservation number of CCTCC NO: M 20221037. The Salmonella phage nct1 has small toxic and side effects, high safety, a relatively wide temperature and acid-base tolerance range, and good killing and prevention and control effects on environments, foods and the like contaminated by Salmonella and pathogenic Escherichia coli.

The invention discloses an epidemic disease prevention, detection and purification method for Sansui duck breeding, which is used for daily epidemic disease prevention and control of commercial duck farms and breeding duck farms of Sansui ducks, and comprises the following steps: S1, epidemic disease detection and screening aiming at duck tembusu virus disease, riemerella anatipestifer disease and duck poultry pathogenic colibacillosis; s2, obtaining a detection result in the step S1 for isolation; s3, breeding monitoring and activity track analysis are checked for infection prevention; s4, disinfecting the functional area during a non-epidemic period, collecting an environmental swab, and laying an infection prevention area; s5, after the S3 and the S4 are executed, the S1 is executed regularly, and continuous monitoring implementation is carried out for more than six months; and S6, when the positive individuals appear in the S5, repeating the steps S3-S5 until no positive individuals exist in the continuous monitoring period. Compared with the prior art, the epidemic disease prevention, detection and purification method for Sansui duck breeding has the advantages of being good in purification, prevention and control effect and capable of synchronously aiming at DTMUV, RA and APEC epidemic diseases.

The invention discloses a B cell conservative epitope peptide of enterotoxigenic Escherichia coli V-type secretion system effect protein EatA and application thereof, and particularly relates to application in ETEC specific antibody diagnosis. The B cell conservative epitope peptide disclosed by the invention can be functionally displayed and expressed on the surface of an inert carrier S9H thallus, PT8 is displayed and expressed on the surface of the S9H thallus, and an agglutination test directly mediated by the PT8 and specifically recognized by an antibody is established, so that only ETEC pathogen infectious antibodies are specifically recognized, other pathogenic escherichia coli can be identified and diagnosed, and the B cell conservative epitope peptide has a good application prospect. And no cross reaction with serum antibodies of other infectious diseases exists. According to the method, the specific serum antibody can be detected 7 days after a Balb / c mouse is infected by the ETEC strain H10407. The diagnosis method is high in specificity, good in sensitivity, convenient to operate and intuitive in result judgment, and is expected to become a technical means for visual on-site accurate and convenient diagnosis of ETEC infection.

The purpose of the present invention is to provide a method for producing an animal model infected with Enterobacteriaceae bacteria such as pathogenic Escherichia coli. Provided is a method for producing an animal model infected with Enterobacteriaceae bacteria, the method comprising step (1) and step (2) in the following order. (1) A step for administering a β-lactam antibacterial agent to a non-human mammal; (2) a step including the following steps (2-1) and (2-2) in random order; (2-1) a step for administering at least one selected from the group consisting of lincomycin antibacterial agents and macrolide antibacterial agents to the non-human mammal; and (2-2) a step for administering Enterobacteriaceae bacteria to the non-human mammal

The invention discloses a lactobacillus amyloliquefaciens and probiotic microbial inoculum and application of the lactobacillus amyloliquefaciens and probiotic microbial inoculum. The lactobacillus amyloporus is named as lactobacillus amyloporus YI39, and the preservation number of the lactobacillus amyloporus YI39 in the China Center for Type Culture Collection is CCTCC (China Center for Type Culture Collection) NO: M2026104; the nucleotide sequence of 16SrDNA (deoxyribonucleic acid) of the gene is SEQ ID NO. 1. The lactobacillus amyloliquefaciens YI39 provided by the invention is separated from ileum contents of 28-day-old healthy and rapid yellow-feathered broilers, has strong probiotic characteristics, and has relatively good capabilities of inhibiting growth of salmonella pullorum, avian pathogenic escherichia coli, A-type clostridium perfringens and staphylococcus aureus; the body of the broiler chicken can be effectively regulated and controlled, so that the chicken necrotic enteritis caused by clostridium perfringens infection is prevented.

The application provides a preparation method of 30S ribosomal protein S1 and use of the 30S ribosomal protein S1 as an antibacterial synergist, and belongs to the technical field of biological medicines. The 30S ribosomal protein S1 in the application is a bioactive protein produced by Acinetobacter bacteria, and has the effect of enhancing the antibacterial capacity of antibiotics. In the process of being combined with streptomycin sulfate, the 30S ribosomal protein S1 greatly enhances the inhibiting capacity of streptomycin sulfate on avian pathogenic E.coli without showing the effect of inhibiting bacteria itself, which lays a foundation for future practical application, and also plays a reference role for the development of new antibacterial synergists.

The invention relates to the technical field of veterinary medicine and animal models, in particular to a modeling method for inducing broiler chicken immunosuppression and secondary bacterial infection. The method comprises the following steps: (a) starting to continuously feed broiler chickens with daily ration containing mycotoxin at the age of 6-10 days until molding is finished; (b) inoculating infectious bursal disease virus on the broiler chicken at the age of 12-16 days; and (c) inoculating avian pathogenic escherichia coli after inoculating the infectious bursal disease virus for a period of time. According to the modeling method, the clinical pathogenesis process is highly simulated, the mechanism fits the reality, the model success rate is high and stable, standardized operation is achieved, repeatability is good, simplicity, convenience and safety are achieved, and the biological safety risk of virulent strains is avoided; the application range is wide, and an excellent platform is provided for research and development; the method is low in cost and suitable for scientific research and large-scale drug screening popularization.

The invention discloses calf-derived lactobacillus reuteri and application thereof in preparation of products for preventing and treating colitis injury, the calf-derived lactobacillus reuteri has been preserved in China General Microbiological Culture Collection Center on October 9, 2025, the preservation address is No. 3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO. The preservation number of the lactobacillus reuteri is CGMCC No.36229, the lactobacillus reuteri is classified and named as lactobacillus reuteri KY-1, and the lactobacillus reuteri can directly inhibit growth of pathogenic escherichia coli, relieve colitis, remarkably relieve inflammation caused by the pathogenic escherichia coli and relieve deep mucosa muscular layer ulcer, gland structure damage and inflammatory cell infiltration caused by the pathogenic escherichia coli. Therefore, the lactobacillus reuteri has a good treatment effect in treating colitis caused by pathogenic escherichia coli, and a theoretical support is provided for medicine development of calf-derived lactobacillus reuteri in the aspect of treating intestinal inflammation.

The application relates to an antibacterial peptide and application thereof, wherein the amino acid sequence of the antibacterial peptide NA is WVKIIKTICRWR, the antibacterial peptide is composed of 12 amino acid residues, has cation amphiphilic characteristics, and can be obtained through chemical synthesis. The antibacterial peptide has stable in-vitro bacteriostatic activity on various serotypes of avian and other animal enteropathogenic Escherichia coli (ExPEC), has good cell compatibility and blood safety in an effective bacteriostatic concentration interval, has low hemolysis rate and small cytotoxicity. The antibacterial peptide can be used for preparing veterinary antibacterial preparations, functional feed additives or animal health management related products, can replace or reduce the use of traditional antibiotics in the breeding field, provides a new technical scheme for the prevention and control of ExPEC related infections, and has important application value.

The invention belongs to the technical field of microorganisms and genetic engineering. The invention provides an avian pathogenic escherichia coli strain resistant to a low-phosphorus environment and a preparation method of the avian pathogenic escherichia coli strain. According to the strain, the integrity of an LPS map can be achieved under the phosphorus concentration of 20-200 [mu] M, the transcription levels of rmlB, rmlD, rmlA, fdtA, fetB, rmlC, wzy, wegR and wegS genes are up-regulated, and the transcription level of rfaH is up-regulated; the strain is named as DE17-delta phoB, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.36537, the strain is preserved in the China General Microbiological Culture Collection Center, and the preservation time is November 7, 2025. It is found that PhoB is phosphorylated in a low-phosphorus environment, and an O-antigen gene cluster is regulated and controlled to participate in O-antigen synthesis, so that the low-phosphorus extreme environment is resisted; meanwhile, PhoB and RfaH are also found to regulate and control the O-antigen and maintain the transcription stability of the O-antigen so as to cope with environmental changes. The invention provides a corresponding research basis for prevention and treatment of avian pathogenic escherichia coli in the future.

The application belongs to the field of biology and specifically provides a protein molecule and application thereof in identifying avian pathogenic E. coli of multiple serotypes, wherein the amino acid sequence of the protein molecule is shown as SEQ ID No: 1. The protein molecule of the application can specifically recognize avian pathogenic E. coli of O2, O18 and O78 antigen serotypes, and can be used for identification and enrichment of avian pathogenic E. coli of O2, O18 and O78 antigen serotypes, and has the advantages of simplicity, rapidness and accuracy, and has high application value.

The invention discloses a primer group and a kit for detecting avian pathogenic escherichia coli based on an LAMP (Loop-Mediated Isothermal Amplification) method, and belongs to the technical field of biological detection. The primer group comprises an upstream outer primer F3, a downstream outer primer B3, an upstream inner primer FIP and a downstream inner primer BIP, the kit comprises the primer group: an upstream outer primer F3, a downstream outer primer B3, an upstream inner primer FIP and a downstream inner primer BIP. The novel avian pathogenic Escherichia coli LAMP primer group is autonomously designed, is used for detecting avian pathogenic Escherichia coli based on a loop-mediated isothermal amplification method and can be applied to kit detection, a result can be obtained by observing color change, and a large amount of time is saved; meanwhile, the lowest detection limit of target strains reaches 3.6 * 100 CFU / mL, and the detection limit is remarkably improved compared with that of a traditional PCR method.

This document describes compositions, methods, and kits for detecting diarrheal pathogens from patient, food, or environmental samples. One embodiment described herein is primer pairs and probes for a multiplex polymerase chain reaction (PCR)-based assay for detecting gastrointestinal pathogens such as adenovirus, astrovirus, rotavirus, norovirus, zaruzin virus, Campylobacter species, Clostridium difficile, enteroaggregative Escherichia coli (EAEC), enteropathogenic Escherichia coli (EPEC), enterotoxin-producing Escherichia coli (ETEC), Shigella-like toxin-producing Escherichia coli (STEC), Shigella spp. / enteroinvasive Escherichia coli (EIEC), Escherichia coli O157, Listeria monocytogenes, Shigella-like bacteria, Salmonella spp., Yersinia enterocolitica, Vibrio species, Cryptosporidium species, Cyclospora kayanoides, Entamoeba histolytica, Giardia lamblia, or Giardia lamblia. Other embodiments include methods and kits for detecting gastrointestinal pathogens.

The invention discloses an application of dimethyl sulfoxide in preparation of a medicament for treating urinary tract infection. The dimethyl sulfoxide disclosed by the invention can inhibit the growth of drug-resistant and non-drug-resistant uropathogenic escherichia coli in vitro or in vivo, and has a bactericidal effect. Dimethyl sulfoxide is used for perfusing the bladder with urinary tract infection, so that colonization of uropathogenic escherichia coli in the bladder can be remarkably reduced, bladder edema and inflammation are relieved, and the bladder function is improved. Particularly, the dimethyl sulfoxide can promote the shedding of infected bladder epithelial cells and relieve inflammatory response. Therefore, the dimethyl sulfoxide disclosed by the invention can be used for preparing the medicine for treating urinary tract infection, has a remarkable curative effect on urinary tract infection caused by multiple drug-resistant pathogens, provides a solution for treating UTI clinical management with increasingly severe antibiotic resistance, and has a wide application prospect.

The application discloses a kind of paragallinarievaccines and preparation method thereof, the paragallinarievaccines include A type paragallinarie, B type paragallinarie and C type paragallinarie HMTp210 hypervariable region protein and avian pathogenic escherichia coli ghost.The application uses three serotypes HMTp210 hypervariable region recombinant protein and avian pathogenic escherichia coli ghost (especially O78 type avian pathogenic escherichia coli ghost) in combination, synergistically enhances humoral and cellular immunity, provides more broad-spectrum protection, while reaching the protection effect equivalent to white oil adjuvant, significantly improves injection safety, avoids the granuloma and other side reactions of white oil adjuvant, realizes the technical goal of "equivalent protection, better safety".